Evaluation of valganciclovir pharmacokinetics in lung transplant recipients

Journal of Heart and Lung Transplantation

Volumn 31, Issue 2, 2012, Pages 159-166

  Kiser, Tyree H ^a   Fish, Douglas N ^a   Zamora, Martin R ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

adverse event; ganciclovir; lung transplant; pharmacokinetics; safety; valganciclovir

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HUMAN; LUNG TRANSPLANTATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIVIRAL AGENTS; CROSS-OVER STUDIES; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; LUNG TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84856428284     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2011.11.016     Document Type: Article

References (20)

1. J.A. Fishman, R.H. Rubin Infection in organ-transplant recipients N Engl J Med 338 1998 1741 1751 (Pubitemid 28268592)
2. M.R. Zamora, R.D. Davis, C. Leonard Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations Transplantation 80 2005 157 163 (Pubitemid 41061670)
3. S.R. Duncan, I.L. Paradis, S.A. Yousem Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients Am Rev Respir Dis 146 1992 1419 1425
4. D.R. Snydman Infection in solid organ transplantation Transpl Infect Dis 1 1999 21 28
5. J.M. McCarthy, M.A. Karim, H. Krueger, P.A. Keown The cost impact of cytomegalovirus disease in renal transplant recipients Transplantation 55 1993 1277 1282 (Pubitemid 23183237)
6. M.E. Falagas, M. Arbo, R. Ruthazer Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients Transplantation 63 1997 1595 1601 (Pubitemid 27265500)
7. W.R. Kim, A.D. Badley, R.H. Wiesner The economic impact of cytomegalovirus infection after liver transplantation Transplantation 69 2000 357 361 (Pubitemid 30118114)
8. M.I. Hertz, C. Jordan, S.K. Savik Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation J Heart Lung Transplant 17 1998 913 920 (Pubitemid 28440855)
9. S.M. Palmer, A.P. Limaye, M. Banks Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial Ann Intern Med 152 2010 761 769
10. Valganciclovir package insert 2010 August Hoffman-La Roche, distributed by: Genentech USA, Inc. San Francisco
11. M.R. Zamora, M.R. Nicolls, T.N. Hodges Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation Am J Transplant 4 2004 1635 1642 (Pubitemid 39312297)
12. D.W. Cockcroft, M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
13. F. Brown, L. Banken, K. Saywell, I. Arum Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers Clin Pharmacokinet 37 1999 167 176 (Pubitemid 29431482)
14. V.P. Shah, K.K. Midha, J.W. Findlay Bioanalytical method validationa revisit with a decade of progress Pharm Res 17 2000 1551 1557 (Pubitemid 32217566)
15. M.D. Pescovitz, J. Rabkin, R.M. Merion Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients Antimicrob Agents Chemother 44 2000 2811 2815
16. A. Caldes, H. Colom, Y. Armendariz Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus Antimicrob Agents Chemother 53 2009 4816 4824
17. H. Wiltshire, S. Hirankarn, C. Farrell Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients Clin Pharmacokinet 44 2005 495 507 (Pubitemid 40733734)
18. H. Wiltshire, C.V. Paya, M.D. Pescovitz Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients Transplantation 79 2005 1477 1483 (Pubitemid 40847577)
19. C.A. Finlen Copeland, W.A. Davis, L.D. Snyder Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial J Heart Lung Transplant 30 2011 990 996
20. Ganciclovir package insert 2010 February Hoffman-La Roche, distributed by: Genentech USA, Inc. San Francisco